MedCity
3615 Superior Ave E, Ste 3102G, Cleveland, OH, 44106, United States
Overview
MedCity News creates content for people who care about health care. It is a solution for media companies and organizations that need content, stakeholders who need actionable information about the medical industry, and advertisers who want to speak to this valuable niche audience. Founded by veteran journalists with both health care reporting and online editorial experience, MedCity News is poised to build an innovative new-media enterprise capable of taking advantage of these converging forces while building a profitable national business and brand. It operates the MedCity News Service, a type of niche wire service focused on the innovation economies in major "medical cities" and states (it has offices in Minnesota and Ohio, but also covers dealflow in the Midwest and Pittsburgh). It also operates MedCityNews.com and a custom content service that creates made-to-order content for anyone that wants it. Its news content is syndicated throughthe Ohio News Network, Akron Beacon Journal, The Kindle, WKYC, the Boston online journal MassDevice and the Zemanta blog aggregator, among others.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Health Care
- News
Investment portfolio
- Sixfold Bioscience
Participated · Seed · Dec 2021
Sixfold Bioscience develops the Mergo® RNA therapeutics delivery platform, combining computational screening, high-throughput chemistry, and iterative testing to identify biocompatible building blocks that target selected cell types. The platform is focused on short interfering RNA for gene silencing and messenger RNA for gene expression. Mergo’s modular building-block approach aims to modulate pharmacokinetics and pharmacodynamics to expand RNA therapeutics beyond the liver and local administration. The company leads a series of collaborations on RNA therapeutics and has received non-dilutive support tied to that work. Sixfold was founded in 2017 by Dr George Foot and Dr Perdrix Rosell and operates from London. The recent financing will support continued R&D and expansion of the platform across several therapeutic indications.